Pulse Biosciences, Inc. (NASDAQ:PLSE – Get Free Report) shares gapped up before the market opened on Friday . The stock had previously closed at $15.66, but opened at $16.36. Pulse Biosciences shares last traded at $16.13, with a volume of 55,647 shares.
Wall Street Analysts Forecast Growth
Separately, StockNews.com raised Pulse Biosciences to a “sell” rating in a report on Thursday, January 2nd.
Get Our Latest Stock Analysis on Pulse Biosciences
Pulse Biosciences Stock Performance
Institutional Trading of Pulse Biosciences
Several hedge funds have recently modified their holdings of the company. Tower Research Capital LLC TRC raised its position in Pulse Biosciences by 98.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,692 shares of the company’s stock valued at $29,000 after purchasing an additional 838 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of Pulse Biosciences in the fourth quarter valued at $44,000. Caisse Des Depots ET Consignations bought a new position in shares of Pulse Biosciences in the fourth quarter valued at about $95,000. Farther Finance Advisors LLC lifted its position in Pulse Biosciences by 44.4% during the 4th quarter. Farther Finance Advisors LLC now owns 7,220 shares of the company’s stock worth $126,000 after buying an additional 2,220 shares in the last quarter. Finally, SG Americas Securities LLC bought a new stake in Pulse Biosciences during the 4th quarter worth about $193,000. Institutional investors and hedge funds own 76.95% of the company’s stock.
Pulse Biosciences Company Profile
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
See Also
- Five stocks we like better than Pulse Biosciences
- How to Buy Gold Stock and Invest in Gold
- JPMorgan: The ‘NVIDIA of Banking’ Poised for More Gains?
- 3 Fintech Stocks With Good 2021 Prospects
- Buy the Chewy Stock Reversal? Here’s Why Now Is the Time
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- Ibotta Stock: Why the Buyback Looks Like a Bullish Bet
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.